Preclinical evaluation of AHR-2244 a new psychotherapeutic agent.
D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D001565:Benzoates / Q000494:pharmacology; D002375:Catalepsy / Q000139:chemically induced; D002415:Cats; D003342:Corpus Striatum / Q000378:metabolism; D003913:Dextroamphetamine / Q000633:toxicity; D018492:Dopamine Antagonists; D004357:Drug Synergism; D004569:Electroencephalography; D005260:Female; D005464:Fluorobenzenes / Q000494:pharmacology; D006591:Hexobarbital / Q000494:pharmacology; D006801:Humans; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010647:Phenyl Ethers / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology*; D010880:Piperidines; D051381:Rats; D014149:Tranquilizing Agents / Q000494:pharmacology*
D001565:Benzoates; D018492:Dopamine Antagonists; D005464:Fluorobenzenes; D010647:Phenyl Ethers; D010879:Piperazines; D010880:Piperidines; D014149:Tranquilizing Agents; C009979:AHR 2244; D006591:Hexobarbital; D003913:Dextroamphetamine